Nearly 30 different ALK-fusion protein partners have been described and the most prevalent fusion partner in NSCLC patients is echinoderm microtubule-associated protein-like 4 (EML4-ALK) [6], [7] (Figure 1), leading to multiple fusions variants of which variant 1 (E13;A20, 33%), variant 2 (E20;A20, 10%), and variants 3 a/b (E6;A20, 29%) are the most frequent fusions [8]. Here, ALK is linked to non-small cell lung carcinoma.